Close Menu

Waters

Qiagen's CEO discussed the company's focus on specific growth drivers, while Invitae's CEO talked about pandemic-related challenges in its genetic testing business.

Waters posted revenues of $593.8 million in Q3 compared to $577.3 million in Q3 2019 and beating the average Wall Street estimate of $546.5 million.

The company posted Q2 revenues of $520.0 million, down 13 percent from $599.2 million in Q2 2019, but above analysts' average estimate of $496.9 million.

The firm's predicted Q2 revenues of $517 million to $523 million beat expectations as former MilliporeSigma CEO Udit Batra becomes president and CEO.

The index outperformed the Dow Jones, the Nasdaq, and the Nasdaq Biotechnology Index in the first half of the year.

The GenomeWeb Index rose more than 2 percent in June, but the increase was subdued compared to the index's 9 percent climb in May and 18 percent hike in April.

While there were a few new mass spectrometry instrument introductions, vendors focused primarily on software and sample separation advances.

Waters posted revenues of $464.9 million for the quarter as the SARS-CoV-2 pandemic drove a drop in sales globally, including a 45 percent decline in China.

Revenues during the quarter were $716.3 million, beating Wall Street estimates, while full year 2019 revenues totaled $2.41 billion.

Pages

Imperial College London researchers are shifting away from testing a COVID-19 vaccine to focus on combating newly emerging SARS-CoV-2 variants, the Independent says.

According to the Associated Press, genetic genealogy has helped law enforcement officials identify an unknown victim of the Green River Killer.

In PNAS this week: target to reduce chemotherapy-induced cardiac injury, tool finds ancient endogenous RNA viruses, and more.

Moderna reports its vaccine is effective against new SARS-CoV-2 strains, though it is also developing a booster, according to the New York Times.